Arestat™ Protein Stabilisation Technology
Arestat™ comprises two fundamentally different aspects of our platform stabilisation technology – Arestat-T™ and Arestat-R™. Both utilise excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability.
Arestat™
Stabilises biologics by controlling the rate of interactions with surrounding molecules.
Arestat™ summary
Arestat-T™ & Arestat-C™
Stabilises biologics in storage at refrigerated, ambient and elevated temperatures.
Proton exchange Metal ion interactions Hydrophobic interactions Control of hydrolysis
Arestat-R™
Stabilises biologics during and after sterilisation by a standard dose of ionising radiation.
Ionising radiation
Both are available for licensing for therapeutic proteins, vaccines, medial devices and diagnostics.
Case Studies
Application of Arestat™ formulations are illustrated in the case studies selected from Arecor’s in-house projects and several partnered projects.
Conferences & Events
Arecor will be attending the forthcoming events:
4th Pre-filled Syringe Conference London, 19th October 2011
World Vaccines Congress Lyon, 10th - 13th October 2011
BioProcess International Longbeach, CA, Oct - 4th Nov 2011
BNAC Conference New York, 3rd - 6th November 2011
JP Morgan San Francisco, 9th - 12th January 2012
Drug Delivery and Formulation Berlin, 16th - 18th January 2012
Drug Delivery Partnerships Las Vegas, 24th - 27th January 2012
Click on the icon to download Arecor presentations from the following events:
EventLocationDate 
BioProcess UK Brighton, UK 27/11/2008
Biosimilars Conference Philadelphia, USA 01/11/2008
Biosimilars Conference Dublin 01/06/2008
BioEurope Spring Madrid 01/04/2008
©Arecor 2009. All rights reserved. Designed & developed by The Refinery